지혈제 시장 : 제품별, 형태별, 용도별, 최종 사용자별, 지역별(2024-2031년)

Hemostats Market Valuation - 2024-2031

The advancements in surgical techniques, an increasing number of surgical procedures worldwide, and a rising prevalence of chronic diseases requiring surgical interventions. Thus, the technological advancements in surgical techniques surge the growth of market size surpassing USD 2.7 Billion in 2024 to reach the valuation of USD 4.25 Billion by 2031.

The ongoing innovations in hemostat materials and technologies, increasing healthcare expenditure in emerging economies, and a growing aging population require more surgical procedures. Thus, the ongoing innovations enable the market to grow at aCAGR of 5.81% from 2024 to 2031.

Hemostats Market: Definition/ Overview

Hemostats are medical devices or agents designed to control bleeding during surgical procedures or in cases of traumatic injury. These products work by promoting blood clotting (coagulation) or by mechanically sealing off blood vessels to stop blood flow. Hemostats play a crucial role in various medical fields, including general surgery, cardiovascular surgery, neurosurgery, and emergency medicine.

Furthermore, hemostats come in various forms, including mechanical devices like clips and staples, as well as absorbable and non-absorbable materials such as gelatin-based sponges, oxidized regenerated cellulose, and collagen-based products. Advanced hemostats may incorporate active biological components like thrombin or fibrin to enhance their effectiveness. The choice of hemostat depends on the specific surgical procedure, the type and severity of bleeding, and patient factors.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Potential Impacts of Advanced Hemostatic Technologies on the Surgical Industry?

Advanced hemostatic technologies are poised to significantly impact the surgical industry by enhancing procedural efficiency and patient outcomes. These innovations, including nanoparticle-based hemostats and smart materials that respond to bleeding conditions, promise to reduce surgical time and minimize blood loss more effectively than traditional methods. By providing surgeons with more precise and rapid bleeding control, these technologies could enable more complex procedures to be performed with reduced risk, potentially expanding the range of treatable conditions and improving success rates in challenging surgeries.

Furthermore, advanced hemostats could lead to shorter recovery times and reduced complications for patients, potentially decreasing hospital stays and healthcare costs. The integration of these technologies with minimally invasive and robotic surgical systems may also drive a shift towards less invasive procedures, benefiting patients through smaller incisions and faster healing. As these advanced hemostats become more widely adopted, they could reshape surgical protocols and training, necessitating new skills for healthcare professionals and potentially altering the landscape of surgical specialties.

How Will Changes in Healthcare Policies Affect the Adoption of Hemostatic Products?

Changes in healthcare policies are likely to have a significant impact on the adoption of hemostatic products. As healthcare systems worldwide increasingly focus on cost-effectiveness and patient outcomes, policies that promote value-based care may accelerate the adoption of advanced hemostats. These products, while potentially more expensive upfront, can reduce overall healthcare costs by decreasing surgical complications, shortening hospital stays, and improving patient recovery times. Policies that incentivize hospitals and surgeons to improve efficiency and reduce readmission rates may drive increased use of effective hemostatic solutions.

Furthermore, regulatory changes aimed at enhancing patient safety and reducing adverse events during surgeries could boost the adoption of newer, more effective hemostatic products. Policies that streamline the approval process for innovative medical devices, particularly those addressing critical needs in surgical care, may lead to faster market entry for advanced hemostats. Additionally, healthcare reforms that expand access to surgical procedures in developing countries could significantly increase the global demand for hemostatic products, as these nations seek to improve their surgical capabilities and outcomes.

Category-Wise Acumens

How does the Increasing Prevalence of Cardiovascular Diseases Surge the Growth of the Cardiovascular Surgery Segment?

The cardiovascular surgery segment dominates the hemostats market. Cardiovascular procedures, such as coronary artery bypass grafting and heart valve replacements, often involve complex manipulations of highly vascularized tissues, making effective bleeding control crucial. The increasing prevalence of cardiovascular diseases globally, coupled with advancements in cardiac surgical techniques, has led to a rise in the number of these procedures. This trend has created a substantial and growing demand for specialized hemostatic products that can address the unique challenges of cardiac surgeries, such as the need for rapid and durable hemostasis in a dynamic, high-pressure environment.

Furthermore, the critical nature of cardiovascular surgeries means that surgeons often prefer advanced hemostatic solutions that offer superior efficacy and reliability. This preference is driving innovation in the hemostat market, with manufacturers developing products specifically tailored for cardiovascular applications. These may include products with enhanced adhesive properties to withstand blood pressure or those that can be applied in minimally invasive cardiac procedures. As cardiovascular surgeries continue to evolve, becoming less invasive and more complex, the demand for sophisticated hemostats is expected to grow, further propelling the overall market expansion and shaping product development strategies in the industry.

How does the Increasing Frequency of Emergency Surgeries in Hospital Settings Surge the Growth of the Hospital Segment?

The hospital segment dominates the hemostats market driven by the increasing frequency of emergency surgeries in hospital settings, which is significantly boosting the hemostats market. As trauma cases, acute medical conditions, and unforeseen complications rise, hospitals face a growing need for rapid and effective bleeding control solutions. Emergency surgeries often involve critical situations where time is of the essence, and conventional hemostatic methods may be insufficient. This urgent demand drives the adoption of advanced hemostatic products that can quickly and reliably stop bleeding, even in challenging conditions. Consequently, hospitals invest in a diverse range of hemostats to ensure they are well-equipped to handle various emergencies.

Furthermore, the unpredictable nature of emergency surgeries necessitates that hospitals maintain a robust inventory of hemostatic products. This requirement leads to consistent and potentially increasing orders from hospital systems, providing a steady growth driver for the hemostats market. The emphasis on improving emergency care outcomes also encourages the development and adoption of innovative hemostatic technologies specifically designed for rapid deployment in high-pressure situations. As hospitals strive to enhance their emergency surgical capabilities, the demand for versatile, easy-to-use, and highly effective hemostats continues to grow, further stimulating market expansion and product innovation in the hemostats sector.

Country/Region-wise Acumens

What Role Do Regulatory Frameworks in North America Play in Shaping the Development of Hemostatic Products?

North America substantially dominates the hemostats market owing to the regulatory frameworks in North America, particularly those established by the U.S. Food and Drug Administration (FDA) and Health Canada, which play a crucial role in shaping the development of hemostatic products. These agencies set stringent standards for safety, efficacy, and quality, which directly influence product design, testing protocols, and manufacturing processes.

The FDA's premarket approval (PMA) process for Class III medical devices, which includes many advanced hemostatic products, requires extensive clinical trials and data submission. This rigorous approach drives manufacturers to invest heavily in research and development, leading to innovative products with demonstrated safety and effectiveness. Additionally, post-market surveillance requirements encourage ongoing refinement and improvement of hemostatic technologies, ensuring their continued safety and efficacy in real-world clinical settings. These regulatory frameworks ultimately foster a culture of continuous innovation while maintaining high standards for patient safety.

What Role Does the Expanding Medical Tourism Sector in Asia Pacific Play in Boosting the Demand for Hemostats?

Asia Pacific is anticipated to witness the fastest growth in the hemostats market during the forecast period owing to the growth of medical tourism has led to an increase in complex surgical procedures being performed in the region. Countries like Thailand, Singapore, and India have become popular destinations for a wide range of surgeries, from cosmetic procedures to organ transplants. This surge in surgical activity naturally drives up the demand for hemostatic products, which are essential for managing bleeding during and after operations. As these countries strive to offer world-class medical services, they are investing in advanced hemostatic technologies to ensure optimal patient outcomes and maintain their competitive edge in the global medical tourism market.

Furthermore, the medical tourism sector's emphasis on quality and patient safety has raised standards across the healthcare industry in Asia Pacific. To attract international patients, hospitals and clinics are adopting the latest medical technologies, including advanced hemostatic products. This trend is not limited to premier hospitals catering to medical tourists but is also influencing local healthcare providers who are upgrading their facilities and practices to compete. Consequently, the demand for high-quality hemostats is increasing across the broader healthcare landscape, driven by the ripple effect of medical tourism's quality standards.

Competitive Landscape

The Hemostats Market is exceptionally competitive, driven by product innovation, different formulations, and rising surgical demand. To increase market share, key players prioritize technical developments and global expansion.

Some of the prominent players operating in the hemostats market include:

CR Bard, Inc.

Braun Melsungen AG

Baxter International, Inc.

Integra LifeSciences

Marine Polymer Technologies, Inc.

Teleflex

Ethicon, Inc.

Pfizer, Inc.

Z-Medica LLC

Gelita Medical GmbH

Anika Therapeutics, Inc.

Stryker

Latest Developments

In March 2024, Baxter International announced the launch of an advanced fibrin sealant Baxter introduced a next-generation fibrin sealant with improved adhesive properties and faster clotting time.

In January 2024, Ethicon (Johnson & Johnson) expanded its hemostatic powder portfolio Ethicon received FDA approval for a new formulation of its hemostatic powder, designed for minimally invasive surgeries.

In November 2023, Integra LifeSciences announced the acquisition of regenerative medicine startup Integra LifeSciences acquired a biotech company specializing in plant-based hemostatic agents.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEMOSTATS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HEMOSTATS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Drivers
• 4.4 Restraints
• 4.5 Opportunities
• 4.6 Porters Five Force Model
• 4.7 Value Chain Analysis

5 GLOBAL HEMOSTATS MARKET, BY END USER

• 5.1 Overview
• 5.2 Clinics
• 5.3 Hospitals
• 5.4 Ambulatory Centers

6 GLOBAL HEMOSTATS MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Thrombin-Based Hemostats
• 6.3 Oxidized Regenerated Cellulose-Based Hemostats
• 6.4 Collagen-Based Hemostats
• 6.5 Polysaccharide Hemostats

7 GLOBAL HEMOSTATS MARKET, BY FORMULATION

• 7.1 Overview
• 7.2 Matrix & Gel Hemostats
• 7.3 Sheet & Pad Hemostats
• 7.4 Powder Hemostats
• 7.5 Sponge Hemostats

8 GLOBAL HEMOSTATS MARKET, BY APPLICATION

• 8.1 Overview
• 8.2 Orthopedic Surgery
• 8.3 General Surgery
• 8.4 Neurological Surgery
• 8.5 Cardiovascular Surgery
• 8.6 Gynecological Surgery

9 GLOBAL HEMOSTATS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL HEMOSTATS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 CR Bard, Inc
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 B. Braun Melsungen AG
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Baxter International, Inc.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Integra LifeSciences
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Marine Polymer Technologies, Inc.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Teleflex
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Ethicon, Inc.
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Pfizer, Inc.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Z-Medica LLC
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Gelita Medical GmbH
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Research